Pulse Biosciences, Inc. Appoints Liane R. Teplitsky as Chief Operating Officer with Performance-Based Equity Awards
Key Highlights:
- Liane R. Teplitsky appointed as Chief Operating Officer, effective April 8, 2026.
- Ms. Teplitsky’s compensation package includes significant performance-based equity awards, tied to ambitious market capitalization and revenue milestones.
- Announcement made via Form 8-K and related press release, both public disclosures that may impact market sentiment.
Details of the Appointment and Compensation Structure
Pulse Biosciences, Inc. (“the Company”) announced the appointment of Liane R. Teplitsky as its new Chief Operating Officer (COO), effective April 8, 2026. Ms. Teplitsky will report to both Co-Chairmen of the Board of Directors. This leadership change is a significant development for the Company as it continues its mission in the medical device and biotechnology space.
Performance-Based Equity Awards: Potential Share Price Implications
A notable feature of Ms. Teplitsky’s employment agreement is the structure of her equity compensation, which is closely linked to the Company achieving aggressive growth targets. This structure is designed to align her interests with those of shareholders and could be highly price sensitive if these milestones are achieved.
1. Stock Options:
- Total grant of 500,000 option shares, with vesting tied to performance:
- 133,333 shares vest when the Company reaches a market capitalization of at least \$2 billion for 270 consecutive days and generates at least \$100 million in GAAP product revenue over twelve months.
- 233,334 shares vest upon achieving a market capitalization of at least \$3 billion for 270 consecutive days and at least \$200 million in GAAP product revenue over twelve months.
- 133,333 shares vest when market capitalization hits \$5 billion for 270 consecutive days and GAAP product revenue surpasses \$330 million over twelve months.
2. Restricted Stock Units (RSUs):
- Total grant of 200,000 RSUs, subject to Board approval and vesting based on revenue milestones:
- 50,000 RSUs vest at \$100 million in GAAP product revenue over twelve months.
- 100,000 RSUs vest at \$200 million in GAAP product revenue over twelve months.
- 50,000 RSUs vest at \$300 million in GAAP product revenue over twelve months.
This compensation structure is highly leveraged to the Company’s growth trajectory. If Pulse Biosciences achieves these targets, it would mark a dramatic improvement in both market valuation and product commercialization, likely resulting in significant share price appreciation.
Additional Terms and Corporate Governance
- Ms. Teplitsky has signed the Company’s standard inventions assignment, confidentiality, non-competition, and indemnification agreements for officers and directors.
- The employment agreement includes severance and change-of-control provisions, as well as a commitment to comply with the Company’s policies on confidential information and business opportunities.
- The agreement was executed by both Co-Chairmen, Robert Duggan and Paul LaViolette, and Ms. Teplitsky.
Strategic Importance for Investors
The appointment of a seasoned executive and the heavy emphasis on performance-based equity incentives represent a strong commitment to driving shareholder value. The market capitalization and revenue milestones outlined are ambitious and, if achieved, would not only trigger substantial equity vesting for the COO but could also lead to a material re-rating of the Company’s shares. Investors should closely monitor the Company’s progress toward these targets, as they are likely to be key catalysts for future share price movements.
Press Release Disclosure
The Company issued a press release on April 9, 2026, to publicly announce Ms. Teplitsky’s appointment. The press release and full employment agreement are available as exhibits to the Form 8-K filing, ensuring transparency and regulatory compliance.
Disclaimer: The information provided above is a summary of disclosures made by Pulse Biosciences, Inc. in its Form 8-K filing and related exhibits. This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to review the full filings and consult with their financial adviser before making any investment decisions. The Company’s future performance and share price are subject to various risks and uncertainties, including but not limited to the achievement of the stated milestones.
View PULSE BIOSCIENCES, INC. Historical chart here
